Top

HSS Journal ®

Published in:

01-02-2013 | Review Article

Development of Polymeric Nanocarrier System for Early Detection and Targeted Therapeutic Treatment of Peri-Implant Osteolysis

Authors: P. Edward Purdue, PhD, Adam S. Levin, MD, Ke Ren, Thomas P. Sculco, MD, Dong Wang, PhD, Steven R. Goldring, MD

Published in: HSS Journal ® | Issue 1/2013

Abstract

Background

Extensive research has implicated inflammation as a necessary and causative factor in the development of peri-implant osteolysis, suggesting that such an inflammatory response is the sentinel event for the process. The potential to impact the clinical course of this condition is hampered by the lack of an effective medical therapy, as well as a limited ability for early detection prior to radiographically evident osteolysis. Advances in nanotechnology have allowed for the production of engineered water-soluble nanocarriers, which exploit changes in the microvascular architecture for selective distribution to inflamed tissues. Evaluation of the uptake of the nanocarriers in sites of inflammation has elucidated a novel mechanism of cellular uptake and retention of these particles.

Purpose

The current review discusses the development of a novel, biocompatible, water-soluble nanocarrier utilizing copolymers of N-(2-hydroxypropyl)methacrylamide (HPMA), conjugated to imaging and therapeutic agents for the detection and targeted treatment of inflammatory conditions.

Methods

We performed Medline searches for the terms “periprosthetic osteolysis,” “murine osteolysis model,” “HPMA osteolysis,” and “HPMA inflammation.” These searches identified 631, 306, 1, and 6 articles, respectively. These were then manually searched for articles relevant to the development of mouse models for inflammatory osteolysis and the use of HPMA copolymer technology in mouse models of inflammation.

Results

Promising results in a small animal model of osteolysis have demonstrated the capability for detection prior to the development of bone loss, and have highlighted the utility of nanocarriers for selective drug delivery to the affected tissues.

Conclusions

Challenges to the clinical translation of HPMA nanocarriers in peri-implant osteolysis remain, and the future research directions necessary for human clinical application are reviewed.

Bozic KJ, Kurtz SM, Lau E, Ong K, Vail TP, Berry DJ. The epidemiology of revision total hip arthroplasty in the United States. J Bone Joint Surg Am. 2009;91(1):128–33. doi:10.2106/JBJS.H.00155.PubMedCrossRef

Caicedo MS, Desai R, McAllister K, Reddy A, Jacobs JJ, Hallab NJ. Soluble and particulate Co-Cr-Mo alloy implant metals activate the inflammasome danger signaling pathway in human macrophages: a novel mechanism for implant debris reactivity. J Orthop Res. 2009;27(7):847–54. doi:10.1002/jor.20826.PubMedCrossRef

Clohisy JC, Hirayama T, Frazier E, Han SK, Abu-Amer Y. NF-kB signaling blockade abolishes implant particle-induced osteoclastogenesis. J Orthop Res. 2004;22(1):13–20. doi:10.1016/S0736-0266(03)00156-6.PubMedCrossRef

Cobelli N, Scharf B, Crisi GM, Hardin J, Santambrogio L. Mediators of the inflammatory response to joint replacement devices. Nat Rev Rheumatol. 2011;7(10):600–8. doi:10.1038/nrrheum.2011.128.PubMed

Dumbleton JH, Manley MT, Edidin AA. A literature review of the association between wear rate and osteolysis in total hip arthroplasty. J Arthroplasty. 2002;17(5):649–61.PubMedCrossRef

Koulouvaris P LK, Ivashkiv LB, Bostrom MP, Nestor BJ, Sculco TP, Purdue PE. Expression profiling reveals alternative macrophage activation and impaired osteogenesis in periprosthetic osteolysis. J Orthop Res. 2008;26(1):106–16.

Kurtz SM, Lau E, Ong K, Zhao K, Kelly M, Bozic KJ. Future young patient demand for primary and revision joint replacement: national projections from 2010 to 2030. Clin Orthop Relat Res. 2009;467(10):2606–12. doi:10.1007/s11999-009-0834-6.PubMedCrossRef

Lindstrom TM, Robinson WH. A multitude of kinases—which are the best targets in treating rheumatoid arthritis? Rheum Dis Clin North Am. 2010;36(2):367–83. doi:10.1016/j.rdc.2010.02.005.PubMedCrossRef

Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387–92.PubMed

10.

Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, Teitelbaum SL. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol. 1999;154(1):203–10.PubMedCrossRef

11.

Purdue PE, Koulouvaris P, Potter HG, Nestor BJ, Sculco TP The cellular and molecular biology of periprosthetic osteolysis. Clin Orthop Relat Res. 2007;454:251–61.PubMedCrossRef

12.

Quan LD, Purdue PE, Liu XM, Boska MD, Lele SM, Thiele GM et al. Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy. Arthritis Res Ther. 2010;12(5):R170 doi:10.1186/ar3130.PubMedCrossRef

13.

Rakshit DS, Ly K, Sengupta TK, Nestor BJ, Sculco TP, Ivashkiv LB et al. Wear Debris Inhibition of Anti-Osteoclastogenic Signaling by Interleukin-6 and Interferon-{gamma} Mechanistic Insights and Implications for Periprosthetic Osteolysis. J Bone Joint Surg Am. 2006;88(4):788–99.

14.

Ren K, Purdue PE, Burton L, Quan LD, Fehringer EV, Thiele GM et al. Early detection and treatment of wear particle-induced inflammation and bone loss in a mouse calvarial osteolysis model using HPMA copolymer conjugates. Mol Pharm. 2011;8(4):1043–51. doi:10.1021/mp2000555.PubMedCrossRef

15.

Ren W, Li XH, Chen BD, Wooley PH. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappaB activity. J Orthop Res. 2004;22(1):21–9.PubMedCrossRef

16.

Schmalzried TP, Jasty M, Harris WH. Periprosthetic bone loss in total hip arthroplasty. Polyethylene wear debris and the concept of the effective joint space. J Bone Joint Surg Am. 1992;74(6):849–63.PubMed

17.

Schwarz EM. What potential biologic treatments are available for osteolysis? J Am Acad Orthop Surg. 2008;16 Suppl 1:S72–5.PubMed

18.

Schwarz EM, Benz EB, Lu AP, Goater JJ, Mollano AV, Rosier RN et al. Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis. J Orthop Res. 2000;18(6):849–55.PubMedCrossRef

19.

St Pierre CA, Chan M, Iwakura Y, Ayers DC, Kurt-Jones EA, Finberg RW. Periprosthetic osteolysis: characterizing the innate immune response to titanium wear-particles. J Orthop Res. 2010;28(11):1418–24 doi:10.1002/jor.21149.PubMedCrossRef

20.

Walde TA, Weiland DE, Leung SB, Kitamura N, Sychterz CJ, Engh CA, Jr. et al. Comparison of CT, MRI, and radiographs in assessing pelvic osteolysis: a cadaveric study. Clin Orthop Relat Res. 2005(437):138–44.PubMedCrossRef

21.

Wang D, Goldring SR. The bone, the joints and the Balm of Gilead. Mol Pharm. 2011;8(4):991–3. doi:10.1021/mp200328t.PubMedCrossRef

22.

Wang D, Miller SC, Liu XM, Anderson B, Wang XS, Goldring SR. Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res Ther. 2007;9(1):R2 doi:10.1186/ar2106.PubMedCrossRef

23.

Ward JR, West PW, Ariaans MP, Parker LC, Francis SE, Crossman DC et al. Temporal interleukin-1beta secretion from primary human peripheral blood monocytes by P2X7-independent and P2X7-dependent mechanisms. J Biol Chem. 2010;285(30):23147–58. doi:10.1074/jbc.M109.072793.PubMedCrossRef

24.

Warme BA, Epstein NJ, Trindade MC, Miyanishi K, Ma T, Saket RR et al. Proinflammatory mediator expression in a novel murine model of titanium-particle-induced intramedullary inflammation. J Biomed Mater Res B Appl Biomater. 2004;71(2):360–6.PubMedCrossRef

25.

Wilkinson JM, Hamer AJ, Stockley I, Eastell R. Polyethylene wear rate and osteolysis: critical threshold versus continuous dose-response relationship. J Orthop Res. 2005;23(3):520–5.

26.

Willert HG. Reactions of the articular capsule to wear products of artificial joint prostheses. J Biomed Mater Res. 1977;11(2):157–64.PubMedCrossRef

27.

Wooley PH, Morren R, Andary J, Sud S, Yang SY, Mayton L et al. Inflammatory responses to orthopaedic biomaterials in the murine air pouch. Biomaterials. 2002;23(2):517–26.PubMedCrossRef

28.

www.orthoinfo.com. Official Website of the American Academy of Orthopaedic Surgeons: www.orthoinfo.org. Accessed March 2012.

Title: Development of Polymeric Nanocarrier System for Early Detection and Targeted Therapeutic Treatment of Peri-Implant Osteolysis
Authors: P. Edward Purdue, PhD
Adam S. Levin, MD
Ke Ren
Thomas P. Sculco, MD
Dong Wang, PhD
Steven R. Goldring, MD
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: HSS Journal ® / Issue 1/2013
Print ISSN: 1556-3316
Electronic ISSN: 1556-3324
DOI: https://doi.org/10.1007/s11420-012-9307-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Development of Polymeric Nanocarrier System for Early Detection and Targeted Therapeutic Treatment of Peri-Implant Osteolysis

Abstract

Background

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Successful Treatment of a Recalcitrant Pleural Effusion with Rib Fracture Fixation

Hip Arthroscopy: The Use of Computer Assistance

Successful Fusion of the Proximal Tibiofibular Joint with Osteogenic Protein-1 (OP-1) Augmentation

MRI Diagnosis of Recurrent Pigmented Villonodular Synovitis Following Total Joint Arthroplasty

Extreme Lateral Interbody Fusion (XLIF) in the Thoracic and Thoracolumbar Spine: Technical Report and Early Outcomes

Lumbar Spine Intervertebral Disc Gene Delivery: A Pilot Study in Lewis Rats